acetyl l carnitine cancer L-Carnitine Carnitine Shuttle and Ferroptosis in

: :

27(12): 96772 Xia LJ, Folkers K

This therapy is not recommended for pregnant or breastfeeding women

The carnitine degradation cluster of A

Neurologic and Metabolic Disorders It may also serve as adjunctive therapy in: Chronic fatigue syndromes Diabetic neuropathy Insulin resistance or metabolic syndrome Age-related mitochondrial decline Dosing and Administration Route : IM injection (preferred for general use), IV infusion (under clinical guidance) Typical IM dose : 5001,000 mg, 13 times per week IV use : 12 grams diluted in compatible carrier solution (e.g., saline), infused over 3060 minutes Dosing frequency is patient-specific and may be adjusted based on clinical response , exercise load , or lab values Safety and Considerations L-Carnitine is generally well tolerated when administered properly